Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial for Ropidoxuridine, targeting glioblastoma patients [1][2] - The trial aims to identify an optimal dose of Ropidoxuridine by randomizing 40 patients into two groups, with the goal of demonstrating improved survival compared to historical controls [2][3] - Ropidoxuridine is positioned as a radiation sensitizer to enhance the effectiveness of radiation therapy for glioblastoma, a highly aggressive brain tumor with no known cure [3] Company Overview - Founded in 2012, Shuttle Pharmaceuticals focuses on developing therapies to improve outcomes for cancer patients undergoing radiation therapy [7] - The company aims to increase cancer cure rates, prolong survival, and enhance quality of life through the development of radiation sensitizers [7] Market Opportunity - Approximately 800,000 patients in the US receive radiation therapy annually, with about 50% treated for curative purposes, representing a significant market for radiation sensitizers [5] - The number of patients treated for curative purposes is expected to grow by more than 22% over the next five years, indicating a robust market opportunity for Shuttle Pharmaceuticals [5]
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma